Radiation beads plus immunotherapy: a new hope for advanced liver cancer?

NCT ID NCT05377034

Recruiting now Disease control Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding two drugs (atezolizumab and bevacizumab) after a targeted radiation treatment (SIRT-Y90) can help shrink tumors in people with advanced liver cancer that hasn't spread. About 100 participants will be randomly assigned to receive either the drug combination or a placebo after radiation. The main goal is to see how many patients have their tumors shrink or disappear within 9 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Y-90 resin microspheres (radiation beads) followed by atezolizumab plus bevacizumab (immunotherapy and anti-angiogenic drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer that hasn't spread outside the liver, potentially shrinking tumors and improving outcomes.
What could go wrong: This is a phase 2 trial with only 100 participants, so results are preliminary. The added drugs may cause side effects like fatigue, high blood pressure, or immune reactions, and the combination may not work better than radiation alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, China
Kaohsiung Chang Gung Memorial Hospital
RECRUITING

Kaohsiung City, Taiwan
National Cancer Centre Singapore
RECRUITING

Singapore, 168583, Singapore
National Taiwan University Cancer Center
RECRUITING

Taipei, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, Taiwan
National University Hospital
RECRUITING

Singapore, 119074, Singapore
People's Liberation Army General Hospital (1st and 6th Medical Centre)
NOT_YET_RECRUITING

Beijing, China
Samsung Medical Center
RECRUITING

Seoul, South Korea
Seoul National University Hospital
RECRUITING

Seoul, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, South Korea
Shandong Cancer Hospital
NOT_YET_RECRUITING

Jinan, China
Taichung Veterans General Hospital
RECRUITING

Taichung, Taiwan
Taipei Veterans General Hospital
RECRUITING

Taipei, Taiwan
West China Hospital, Sichuan University
RECRUITING

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.